CASP3 and chronic myelogenous leukemia, BCR-ABL1 positive: Coixol pretreatment reduced caspase-3 activity by 42.8% (p < 0.001 vs. CML), with no significant difference compared to NALC (p = 0.22 vs. coixol) or 4-PBA (p = 0.30 vs. coixol; Figure 5B).